Login Register Cart 0
Generic placeholder image

Recent Patents on Nanotechnology

Editor-in-Chief

ISSN (Print): 1872-2105
ISSN (Online): 2212-4020

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Design Optimization and Evaluation of Solid Lipid Nanoparticles of Azelnidipine for the Treatment of Hypertension

Author(s): Tejas Dugad and Abhishek Kanugo*

Volume 18, Issue 1, 2024

Published on: 11 November, 2022

Page: [22 - 32] Pages: 11

DOI: 10.2174/1872210517666221019102543

Price: $65

Abstract

Background: Solid lipid nanoparticles (SLN) are the most promising lipid-based drug delivery to enhance poorly water-soluble molecules' solubility, bioavailability, and therapeutic efficacy. Azelnidipine (AZN) is a calcium channel blocker widely recommended for treating high blood pressure, but its activity is restricted due to high lipophilicity and poor solubility in the GIT. The current research focused on developing the SLN of AZN and thereby improving the absorption, bioavailability, and therapeutic efficacy in hypertension which is a leading cause of death worldwide. Recent patents on SLN were available as U.S. Patent,10,973,798B2, U.S. Patent 10,251,960B2, U.S. Patent 2021/0069121A1, U.S. Patent 2022/0151945A1.

Methods: SLN was developed by hot melt emulsification and ultrasonication method using glyceryl monostearate (GMS) as solid lipid and Poloxamer 188 as a surfactant to stabilize colloidal dispersion.

Results: Box-Behnken model was utilized, which predicted 13 batches in which concentration of GMS (X1), Poloxamer 188 (X2) and sonication time (X3) were considered independent parameters. The particle size (Y1) and entrapment efficiency (Y2) were dependable parameters, and optimized batch F2 showed a particle size of 166.4 nm, polydispersity index of 0.40 and zeta potential of -13.7 mV. The entrapment efficiency was observed at 86.21%. FTIR spectra confirm the identity and compatibility with the formulation components. The differential scanning calorimetry (DSC) confirmed the absence of melting point and interpreted that AZN was entirely incorporated in the lipid matrix and transformed from crystalline to amorphous. The ANOVA for the particle size (p-value: 0.0203), % EE (p-value: 0.0271) was found significant. The in-vitro drug release showed a sustained release pattern for about 12 h. The AZN-loaded SLN was lyophilized and intended for oral delivery.

Conclusion: AZN-loaded SLN was developed by the hot melt emulsification method, which accelerated the solubility and bioavailability and was released sustainably for treating hypertension.

Keywords: Solid lipid nanoparticles, Azelnidipine, hypertension, Box-Behnken design, oral delivery, DSC.

« Previous Next »
Graphical Abstract

[1]
Kanugo A, Misra A. New and novel approaches for enhancing the oral absorption and bioavailability of protein and peptides therapeutics. Ther Deliv 2020; 713-32.
[http://dx.doi.org/10.4155/tde-2020-0068]
[2]
Kazi MA, Nasr F, Noman O, Alharbi A, Alqahtani MS, Alanazi FK. Development, characterization optimization, and assessment of curcumin-loaded bioactive self-nanoemulsifying formulations and their inhibitory effects on human breast cancer MCF-7 cells. Pharmaceutics 2020; 12(11): 1107.
[http://dx.doi.org/10.3390/pharmaceutics12111107] [PMID: 33217989]
[3]
Berthelsen R, Klitgaard M, Rades T, Müllertz A. In vitro digestion models to evaluate lipid based drug delivery systems; present status and current trends. Adv Drug Deliv Rev 2019; 142: 35-49.
[http://dx.doi.org/10.1016/j.addr.2019.06.010] [PMID: 31265861]
[4]
Chauhan G, Shaik AA, Kulkarni NS, Gupta V. The preparation of lipid-based drug delivery system using melt extrusion. Drug Discov Today 2020; 25(11): 1930-43.
[http://dx.doi.org/10.1016/j.drudis.2020.07.025] [PMID: 32835807]
[5]
Wang JL, Hanafy MS, Xu H, et al. Aerosolizable siRNA-encapsulated solid lipid nanoparticles prepared by thin-film freeze-drying for potential pulmonary delivery. Int J Pharm 2021; 596(596): 120215.
[http://dx.doi.org/10.1016/j.ijpharm.2021.120215] [PMID: 33486021]
[6]
Akanda M, Getti G, Nandi U, Mithu MS, Douroumis D. Bioconjugated Solid Lipid Nanoparticles (SLNs) for targeted prostate cancer therapy. Int J Pharm 2020; 2021: 599.
[http://dx.doi.org/10.1016/j.ijpharm.2021.120416] [PMID: 33647403]
[7]
Kanugo A, Gautam RK, Kamal MA. Recent advances of nanotechnology in the diagnosis and therapy of triple-negative breast cancer (TNBC). Curr Pharm Biotechnol 2022; 23(13): 1581-95.
[http://dx.doi.org/10.2174/1389201023666211230113658] [PMID: 34967294]
[8]
Minocha N, Sharma N, Verma R, Kaushik D, Pandey P. Solid lipid nanoparticles: Peculiar strategy to deliver bio-proactive molecules. Recent Pat Nanotechnol 2022; 16.
[http://dx.doi.org/10.2174/1872210516666220317143351] [PMID: 35301957]
[9]
Yang B, Jiang J, Jiang L, et al. Chitosan mediated solid lipid nanoparticles for enhanced liver delivery of zedoary turmeric oil in vivo. Int J Biol Macromol 2020; 149: 108-15.
[http://dx.doi.org/10.1016/j.ijbiomac.2020.01.222] [PMID: 31987952]
[10]
Mirchandani Y, Patravale VB. S B. Solid lipid nanoparticles for hydrophilic drugs. J Control Release 2021; 335: 457-64.
[http://dx.doi.org/10.1016/j.jconrel.2021.05.032] [PMID: 34048841]
[11]
Kanugo A. Recent advances of nanotechnology in the treatment of skin cancer. Curr Pharm Biotechnol 2022; 23.
[http://dx.doi.org/10.2174/1389201023666220404113242] [PMID: 35379144]
[12]
Geszke-Moritz M, Moritz M. Solid lipid nanoparticles as attractive drug vehicles: Composition, properties and therapeutic strategies. Mater Sci Eng C 2016; 68: 982-94.
[http://dx.doi.org/10.1016/j.msec.2016.05.119] [PMID: 27524099]
[13]
Nasirizadeh S, Malaekeh-Nikouei B. Solid lipid nanoparticles and nanostructured lipid carriers in oral cancer drug delivery. J Drug Deliv Sci Technol 2020; 55(55): 101458.
[http://dx.doi.org/10.1016/j.jddst.2019.101458]
[14]
Kumar S, Randhawa JK. High melting lipid based approach for drug delivery: Solid lipid nanoparticles. Mater Sci Eng C 2013; 33(4): 1842-52.
[http://dx.doi.org/10.1016/j.msec.2013.01.037] [PMID: 23498204]
[15]
Yu LX, Amidon G, Khan MA, et al. Understanding pharmaceutical quality by design. AAPS J 2014; 16(4): 771-83.
[http://dx.doi.org/10.1208/s12248-014-9598-3] [PMID: 24854893]
[16]
Dholakiya A, Dudhat K, Patel J, Mori D. An integrated QbD based approach of SMEDDS and liquisolid compacts to simultaneously improve the solubility and processability of hydrochlorthiazide. J Drug Deliv Sci Technol 2021; 61: 102162.
[http://dx.doi.org/10.1016/j.jddst.2020.102162]
[17]
Zhou B, Perel P, Mensah GA, Ezzati M. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol 2021; 18(11): 785-802.
[http://dx.doi.org/10.1038/s41569-021-00559-8]
[18]
Hypertension. Available from: https://www.who.int/news-room/fact-sheets/detail/hypertension (Accessed on: May 23, 2022).
[19]
Kumar G, Virmani T, Pathak K, Alhalmi A. Review article a revolutionary blueprint for mitigation of hypertension via nanoemulsion 2022; 2022.
[20]
Azelnidipine: Uses, interactions, mechanism of action | DrugBank. Available from: https://go.drugbank.com/drugs/DB09230 (Accessed on: May 24, 2022).
[21]
Gaikwad SS, Avari JG. Improved bioavailability of Azelnidipine gastro retentive tablets-optimization and in-vivo assessment. Mater Sci Eng C 2019; 103: 109800.
[http://dx.doi.org/10.1016/j.msec.2019.109800] [PMID: 31349458]
[22]
Sakellari GI, Zafeiri I, Batchelor H, Spyropoulos F. Formulation design, production and characterisation of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for the encapsulation of a model hydrophobic active. Food Hydrocolloids for Health 2021; 1: 100024.
[http://dx.doi.org/10.1016/j.fhfh.2021.100024] [PMID: 35028634]
[23]
Rai N, Madni A, Faisal A, et al. Glyceryl monostearate based solid lipid nanoparticles for controlled delivery of docetaxel. Curr Drug Deliv 2021; 18(9): 1368-76.
[http://dx.doi.org/10.2174/1567201818666210203180153] [PMID: 33538673]
[24]
Elkarray SM, Farid RM, Abd-Alhaseeb MM, Omran GA, Habib DA. Intranasal repaglinide-solid lipid nanoparticles integrated in situ gel outperform conventional oral route in hypoglycemic activity. J Drug Deliv Sci Technol 2022; 68: 103086.
[http://dx.doi.org/10.1016/j.jddst.2021.103086]
[25]
Kanugo AY, Kochar NI, Chandewar AV. Predictable pulsatile release of candesartan cilexetil for chronotherapeutics of hypertension. Int J Drug Dev Res 2017; 9(2): 42-7.
[26]
Lakshmi KS, Varthan JV. Dispersion of formononetin solid lipid nanoparticles and process for its preparation. U.S. Patent, 10,973,798B2, 2021.
[27]
Shahab MS, Rizwanullah M, Sarim IS. Formulation, optimization and evaluation of vitamin E TPGS emulsified dorzolamide solid lipid nanoparticles. J Drug Deliv Sci Technol 2022; 68(68): 103062.
[http://dx.doi.org/10.1016/j.jddst.2021.103062]
[28]
Yasir M, Chauhan I, Zafar A, et al. Buspirone loaded solid lipid nanoparticles for amplification of nose to brain efficacy: Formulation development, optimization by Box-Behnken design, in-vitro characterization and in-vivo biological evaluation. J Drug Deliv Sci Technol 2021; 61(61): 102164.
[http://dx.doi.org/10.1016/j.jddst.2020.102164]
[29]
Ghiani S, Maiocchi A, Kaminiti L, Miragoli L. Fluorescent solid lipid nanoparticles compositions and method of prepraration thereof. U.S. Patent 10,251,960B2, 2019.
[30]
Sharma S, Kanugo A, Gaikwad J. Design and development of solid lipid nanoparticles of tazarotene for the treatment of psoriasis and acne: a quality by design approach. Mater Technol 2022; 37(8): 735-44.
[http://dx.doi.org/10.1080/10667857.2021.1873637]
[31]
El-Telbany DFA, El-Telbany RFA, Zakaria S, Ahmed KA, El-Feky YA. Formulation and assessment of hydroxyzine HCL solid lipid nanoparticles by dual emulsification technique for transdermal delivery. Biomed Pharmacother 2021; 143: 112130.
[http://dx.doi.org/10.1016/j.biopha.2021.112130] [PMID: 34560549]
[32]
Alhakamy NA, Hosny KM, Aldryhim AY, et al. Development and optimization of ofloxacin as solid lipid nanoparticles for enhancement of its ocular activity. J Drug Deliv Sci Technol 2022; 72: 103373.
[http://dx.doi.org/10.1016/j.jddst.2022.103373]
[33]
Arya RKK, Vijay J, Bisht D, et al. Enhanced brain delivery via intranasal administration of carbamazepine loaded solid lipid nanoparticles: Optimization, pharmacokinetic analysis, in-vitro and in-vivo drug release study. Curr Drug Deliv 2022; 19.
[http://dx.doi.org/10.2174/1567201819666220519120837] [PMID: 35598246]
[34]
Tzachev CT. Solid lipid nanoparticles for intracellular release of active substances and method for production of the same. U.S. Patent 2021/0069121A1, 2021.
[35]
Rampaka R, Ommi K, Chella N. Role of solid lipid nanoparticles as drug delivery vehicles on the pharmacokinetic variability of Erlotinib HCl. J Drug Deliv Sci Technol 2021; 66: 102886.
[http://dx.doi.org/10.1016/j.jddst.2021.102886]
[36]
Kaur IP, Kakkar V, Sandhu SK, Gupta T. Solid lipid nanoparticles of Curcumin. U.S. Patent 2022/0151945A1, 2022.
[37]
Kraisit P, Hirun N, Mahadlek J, Limmatvapirat S. Fluconazole-loaded solid lipid nanoparticles (SLNs) as a potential carrier for buccal drug delivery of oral candidiasis treatment using the Box-Behnken design. J Drug Deliv Sci Technol 2021; 63(63): 102437.
[http://dx.doi.org/10.1016/j.jddst.2021.102437]
[38]
Routray SB, Patra CN, Raju R, Panigrahi KC, Jena GK. Lyophilized SLN of Cinnacalcet HCl: BBD enabled optimization, characterization and pharmacokinetic study. Drug Dev Ind Pharm 2020; 46(7): 1080-91.
[http://dx.doi.org/10.1080/03639045.2020.1775632] [PMID: 32486863]
[39]
Uppuluri CT, Ravi PR, Dalvi AV. Design, optimization and pharmacokinetic evaluation of Piribedil loaded solid lipid nanoparticles dispersed in nasal in situ gelling system for effective management of Parkinson’s disease. Int J Pharm 2021; 606: 120881.
[http://dx.doi.org/10.1016/j.ijpharm.2021.120881] [PMID: 34273426]

Rights & Permissions Print Cite
Article Metrics
28
3
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy